Friday, February 1, 2013

• Shire agrees to settle ADHD drug inquiryAP (Fri, Feb 1)
• Shire Reaches Agreement in Principle With U.S. GovernmentPR Newswire (Fri, Feb 1)

Thursday, January 31, 2013

• FTSE 100 Contrarian: Investing in the Losersat Motley Fool (Thu, Jan 31)

Tuesday, January 22, 2013

• Attention Deficit Disorder Diagnoses Rise 24% in U.S.at Bloomberg (Tue, Jan 22)

Tuesday, January 8, 2013

• Shire says it expects to meet estimates in 2013AP (Tue, Jan 8)

Tuesday, December 18, 2012

• Shire Wins European Backing for Vyvanse Attention Deficit Drugat Bloomberg (Tue, Dec 18)

Thursday, December 6, 2012

• Are These the 5 Worst Retirement Shares in the FTSE?at Motley Fool (Thu, Dec 6)

Monday, December 3, 2012

• Teens Not Overtreated for Mental Illness, Study Suggestsat Bloomberg (Mon, Dec 3)

Tuesday, November 27, 2012

• Buccaneers’ Wright Is Latest NFL Player Banned for Adderall Useat Bloomberg (Tue, Nov 27)

Monday, November 26, 2012

• Head to Head: Shire vs. Smith & Nephewat Motley Fool (Mon, Nov 26)

Wednesday, November 21, 2012

• Adults With ADHD Commit Fewer Crimes When Medicatedat Bloomberg (Wed, Nov 21)

Monday, November 19, 2012

• 10 Shares Trading Near 52-Week Lowsat Motley Fool (Mon, Nov 19)

Friday, November 16, 2012

• Are These the Ultimate Retirement Shares?at Motley Fool (Fri, Nov 16)

Sunday, November 11, 2012

• Is Shire the Ultimate Retirement Share?at Motley Fool (Sun, Nov 11)

Monday, October 29, 2012

• 3 FTSE Losers of the Last 7 Daysat Motley Fool (Mon, Oct 29)

Thursday, October 25, 2012

• Shire CEO to Retire in 2013; Bayer’s Ornskov Gets Top Jobat Bloomberg (Thu, Oct 25)
• Shire 3Q income rises; CEO Russell will retireAP (Thu, Oct 25)
• Shire Says CEO Russell to Retire in 2013; Ornskov Joins Boardat Bloomberg (Thu, Oct 25)

Tuesday, October 9, 2012

• 10 Shares Trading Near 52-Week Lowsat Motley Fool (Tue, Oct 9)

Tuesday, September 25, 2012

• Cosmo Pharma CEO Sees $1.5 Billion Dye Luring Buyer by 2013at Bloomberg (Tue, Sep 25)

Friday, September 21, 2012

• //C O R R E C T I O N//Myeloma Therapies, Hepatitis C Treatments, Colorectal Cancer Drugs, Phase III Trials for Hsp90 Inhibitor: Medical Breakthroughs are Powering Biotech Sector HigherWall Street Transcript (Fri, Sep 21)
• Colorectal Cancer Drug Regorafenib Receives Approval, Carfilzomib Approved for Myeloma Therapy, Hepatitis C Treatments, Phase III Trials for Hsp90 Inhibitor: Medical Breakthroughs are Powering Biotech Sector HigherWall Street Transcript (Fri, Sep 21)

Thursday, September 6, 2012

• Shire settles Intuniv lawsuits with TWi, AnchenAP (Thu, Sep 6)

Wednesday, August 22, 2012

• 10 Shares the Market Lovesat Motley Fool (Wed, Aug 22)

Wednesday, August 15, 2012

• 3 Stocks Set to Beat the S&P Todayat Motley Fool (Wed, Aug 15)

Add SHP.L News to My Yahoo!